New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in…
Novartis announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA). The…
Read More...
Read More...
